Open AccessPB1821: COMBINATION OF BCL‐2 INHIBITOR, HYPOMETHYLATION AGENTS AND LOW‐DOSE CYTARABINE AS A SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
Author(s) -
Gao X.N.,
Lou X.,
Lin J.,
Su Y.F.,
Wang J.,
Xu L.,
Yu H.,
Wang A.,
Wang Y.Z.,
Liu D.H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850136.22948.60
Subject(s) - cytarabine , venetoclax , medicine , decitabine , myeloid leukemia , regimen , oncology , myelodysplastic syndromes , salvage therapy , leukemia , myeloid , gemtuzumab ozogamicin , chemotherapy , bone marrow , chronic lymphocytic leukemia , cd33 , stem cell , biology , biochemistry , gene expression , dna methylation , gene , genetics , cd34